Login / Signup

Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy.

Takahiro YoshidaTaketo KawaiKanade HagiwaraKazuki YanagidaMichio NodaYuumi TokuraItsuki YoshimuraTomoyuki KanekoTohru Nakagawa
Published in: Japanese journal of clinical oncology (2024)
Lower baseline serum testosterone levels predict poor prognosis in patients with metastatic hormone-sensitive prostate cancer.
Keyphrases
  • poor prognosis
  • prostate cancer
  • long non coding rna
  • radical prostatectomy
  • replacement therapy
  • stem cells